154
Views
0
CrossRef citations to date
0
Altmetric
Articles

Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation

, , , , , , ORCID Icon & show all
Pages 2436-2443 | Received 08 Jan 2022, Accepted 01 Apr 2022, Published online: 28 Apr 2022

References

  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
  • Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–2279.
  • Ye Q, Xu-Monette ZY, Tzankov A, et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016;7(3):2401–2416.
  • Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin lymphoma. Bone Marrow Transplant. 2004;33(3):291–298.
  • Porrata LF, Burgstaler EA, Winters JL, et al. Immunologic autograft engineering and survival in non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2016;22(6):1017–1023.
  • Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
  • Hamlin P, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102(6):1989–1996.
  • Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361.
  • Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol. 2017;35(20):2260–2267.
  • Herrera AF, Mei M, Low L, et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35(1):24–31.
  • Cheson BD, Fisher RI, Barrington SF, United Kingdom National Cancer Research Institute, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin’s and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Kaplan F, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53(282):457–481.
  • Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187–202.
  • Chen AI, Leonard JT, Okada CY, et al. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma. Leuk Lymphoma. 2018;59(8):1884–1889.
  • Othman J, Armytage T, Wong K, et al. Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma. Bone Marrow Transplant. 2020;55(7):1460–1463.
  • Laude M-C, Lebras L, Sesques P, et al. First-line treatment of double-hit and triple-hit lymphomas: survival and tolerance data from a retrospective multicenter French study. American J Hematol. 2021;96(3):302–311.
  • Takahashi T, Suzuki R, Yamamoto G, et al. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan. Hematol Oncol. 2021;39(1):66–74.
  • Schuster SJ, Bishop MR, Tam CS, JULIET Investigators, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
  • Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42.
  • Deol A, Uberti J. Rapid and sustained response to chimeric antigen receptor T cell therapy in double hit diffuse large B cell lymphoma . Am J Hematol. 2020;95(3):333–334.
  • Wei J, Mao Z, Wang N, et al. Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy. Clin Transl Med. 2020;10(5):e176.
  • Porrata LF, Inwards DJ, Ansell SM, et al. Autograft immune content and survival in non-Hodgkin's lymphoma: a post hoc analysis. Leuk Res. 2019;81:1–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.